Long-term JAK Inhibitor Treatment for Psoriatic Arthritis (PsA)
Sponsored by AbbVie Medical Affairs
Read for an overview of long-term results from SELECT-PsA 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory PsA patients. Jun 01, 2022